Inhibrx Biosciences (INBX) Stock Analysis: AI Score & Alternative Data
Inhibrx Biosciences — alt-data steady across 90 days
Is Inhibrx Biosciences a buy right now? The alternative data says hold. This INBX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Inhibrx Biosciences every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 47/100: a Hold. The stock trades at $93.41 with a $1B market cap.
No core signal has moved more than 5% in 90 days — steady, but without the momentum that pushes a stock into buy territory.
INBX’s broader alt-data profile also covers headcount (110 employees, according to LinkedIn), web traffic (7K monthly visits), and sentiment (100/100). Every signal links to its own page with full history, the INBX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on INBX is just below.
Inhibrx Biosciences AI Stock Analysis
Inhibrx Biosciences is a biotechnology firm focused on the development and commercialization of novel therapies for serious diseases. The company’s innovative approach leverages advanced protein engineering to create biologics designed to address unmet medical needs.
Analysis generated September 28, 2026.
Recent Inhibrx Biosciences Stock Alerts
|
Inhibrx Biosciences | September 30 Insider Alert: Lappe Mark is buying shares |
|
Inhibrx Biosciences | September 24 Insider Alert: Kayyem Jon Faiz is buying shares |
|
Inhibrx Biosciences | September 23 Price is down by -6.1% in the last 24h. |
|
Inhibrx Biosciences | September 9 Price is up by 7.3% in the last 24h. |
Inhibrx Biosciences Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 7K | N/A | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 110 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 15 | N/A | |
| Stocktwits Mentions | 5 | 16.7% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 822 | N/A |
About Inhibrx Biosciences (INBX)
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
| Price | $93.41 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $1B |
| Year Range | $28 – $142 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Inhibrx Biosciences News
View more → |
Adding an Experimental OX40 Drug to Keytruda Nearly Doubled Tumor Responses in Advanced Head and Neck CancerSeptember 10 - Medical Daily |
 |
Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC StudySeptember 8 - PRNewswire |
 |
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC StudySeptember 4 - PRNewswire |
 |
Inhibrx Reports Second Quarter 2026 Financial ResultsAugust 13 - PRNewswire |
See Inhibrx Biosciences’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for INBX, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEInhibrx Biosciences Earnings & Financial Performance
View all earnings →Inhibrx Biosciences Insider Trading Activity
View all →| Lappe Mark filed to sell 737,548 shares at $0.0. Sep 28 '26 |
| Lappe Mark filed to sell 740,548 shares at $0.0. Sep 28 '26 |
| Lappe Mark filed to sell 736,048 shares at $0.0. Sep 25 '26 |
| Lappe Mark filed to sell 733,872 shares at $0.0. Sep 25 '26 |
| Kayyem Jon Faiz filed to sell 434,360 shares at $0.0. Sep 23 '26 |
Inhibrx Biosciences Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Inhibrx Biosciences
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
ArriVent BioPharmaAVBP |
$15.09 47.0% | $1B | 50 |
 |
OmerosOMER |
$18.51 2.1% | $1B | 50 |
 |
Alpha Tau MedicalDRTS |
$14.48 2.8% | $1B | 43 |
 |
KalVista PharmaKALV |
$27.00 0.0% | $1B | 62 |
 |
Taysha Gene TherapiesTSHA |
$4.39 2.2% | $1B | 52 |
Explore Inhibrx Biosciences Data
Frequently Asked Questions: Inhibrx Biosciences (INBX)
Inhibrx Biosciences has an AltIndex AI Score of 47/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
47/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Inhibrx Biosciences (INBX) stock is $93.41 with a market cap of $1B.
As of today, Inhibrx Biosciences’s PE (Price to Earnings) ratio is —.
View the latest Inhibrx Biosciences insider transactions to see recent buying and selling activity by company executives and directors.
Check the Inhibrx Biosciences congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The INBX stock price chart above shows Inhibrx Biosciences’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Inhibrx Biosciences technical analysis for RSI, moving averages, and more.
See the stocks similar to Inhibrx Biosciences section on this page for companies in the same industry ranked by market cap and AI Score.
